Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Saxagliptin on Left Ventricular Volumes in Patients with Type 2 Diabetes Mellitus and Heart Failure
2015-004825-14Phase 4Terminated
- Sponsor
- AstraZeneca
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), heart failure (HF) and coronary arteriosclerosis comparing Saxagliptin with Placebo (2 arms). Primary endpoint: Change from baseline in LVEDV index. Started Mar 2016; status: terminated.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)coronary arteriosclerosis
Beyond the preview
Go deeper on 2015-004825-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004825-14.